ICU Medical, Inc. (ICUI)
NASDAQ: ICUI · Real-Time Price · USD
160.99
+2.30 (1.45%)
At close: Feb 4, 2025, 4:00 PM
158.75
-2.24 (-1.39%)
Pre-market: Feb 5, 2025, 5:04 AM EST
ICU Medical Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for ICU Medical stock have an average target of 199.67, with a low estimate of 190 and a high estimate of 209. The average target predicts an increase of 24.03% from the current stock price of 160.99.
Analyst Consensus: Buy
* Price targets were last updated on Dec 11, 2024.
Analyst Ratings
The average analyst rating for ICU Medical stock from 4 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 2 | 1 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 1 | 1 | 2 | 2 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 5 | 5 | 5 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Jefferies | Jefferies | Hold → Strong Buy Upgrades $200 | Hold → Strong Buy | Upgrades | $200 | +24.23% | Dec 11, 2024 |
| Keybanc | Keybanc | Buy Maintains $198 → $209 | Buy | Maintains | $198 → $209 | +29.82% | Nov 13, 2024 |
| Needham | Needham | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Nov 13, 2024 |
| Keybanc | Keybanc | Buy Maintains $147 → $198 | Buy | Maintains | $147 → $198 | +22.99% | Oct 15, 2024 |
| Jefferies | Jefferies | Hold Initiates $183 | Hold | Initiates | $183 | +13.67% | Oct 14, 2024 |
Financial Forecast
Revenue This Year
2.36B
from 2.26B
Increased by 4.38%
Revenue Next Year
2.37B
from 2.36B
Increased by 0.34%
EPS This Year
5.71
from -1.23
EPS Next Year
7.27
from 5.71
Increased by 27.28%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 2.4B | 2.5B | 2.7B | ||
| Avg | 2.4B | 2.4B | 2.4B | ||
| Low | 2.2B | 2.0B | 2.1B |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 8.3% | 8.1% | 12.6% | ||
| Avg | 4.4% | 0.3% | 3.0% | ||
| Low | -0.8% | -13.9% | -10.5% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 5.95 | 7.83 | 9.38 | ||
| Avg | 5.71 | 7.27 | 8.71 | ||
| Low | 5.43 | 6.53 | 8.03 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | 37.1% | 28.9% | ||
| Avg | - | 27.3% | 19.8% | ||
| Low | - | 14.2% | 10.4% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.